SCHEMBL3389087

SCHEMBL3389087

O=C(O)/C(=C/c1cccs1)c1ccc(Br)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.57
GCK P35557 3/20 0.49
AKR1C3 P42330 2/20 0.47
KMT2A Q03164 2/20 0.44
HCAR2 Q8TDS4 1/20 0.44
ABL1 P00519 1/20 0.43
BCR P11274 1/20 0.43
AKR1C1 Q04828 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.41
AKR1C2 P52895 1/20 0.40
CYP1A2 P05177 1/20 0.40
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
NFKB1 P19838 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3389090 1.00 MAPT (0.57) MAPTGCKAKR1C3KMT2AHCAR2
SCHEMBL2651868 0.87 GCK (0.61) GCKAKR1C3KMT2AHCAR2AKR1C1
SCHEMBL2651866 0.87 GCK (0.61) GCKAKR1C3KMT2AHCAR2AKR1C1
SCHEMBL9071832 0.84 GCK (0.49) MAPTGCKKMT2AHCAR2AKR1C1
SCHEMBL3393404 0.81 KMT2A (0.51) MAPTGCKKMT2AHCAR2NPC1
SCHEMBL3393395 0.81 KMT2A (0.51) MAPTGCKKMT2AHCAR2NPC1
SCHEMBL2659815 0.80 GCK (0.65) GCKAKR1C3AKR1C1AKR1C2
SCHEMBL3387879 0.80 MAPT (0.61) MAPTGCKKMT2ANPC1LMNA
SCHEMBL2659818 0.80 GCK (0.65) GCKAKR1C3AKR1C1AKR1C2
SCHEMBL3387883 0.80 MAPT (0.61) MAPTGCKKMT2ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168962-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2010-03-31 EP disclosed
US-7582632-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2009-09-01 US disclosed
US-7582632-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2009-09-01 US disclosed
US-7582632-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2009-09-01 US disclosed
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-7214681-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2007-05-08 US disclosed
US-7214681-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2007-05-08 US disclosed
US-7214681-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2007-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS IAPP, GPR119, SLC5A1 MAPT 1611/4885GCK 70/4885AKR1C3 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.